Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311397364> ?p ?o ?g. }
- W4311397364 endingPage "1546" @default.
- W4311397364 startingPage "1546" @default.
- W4311397364 abstract "Cancers and neurological disorders are two major types of diseases. We previously developed a new concept termed “Aberrant Cell Cycle Diseases” (ACCD), revealing that these two diseases share a common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase/oncogene activation and tumor suppressor inactivation, which are hallmarks of both tumor growth in cancers and neuronal death in neurological disorders. Therefore, some cancer therapies (e.g., kinase inhibition, tumor suppressor elevation) can be leveraged for neurological treatments. The United States Food and Drug Administration (US FDA) has so far approved 74 kinase inhibitors, with numerous other kinase inhibitors in clinical trials, mostly for the treatment of cancers. In contrast, there are dire unmet needs of FDA-approved drugs for neurological treatments, such as Alzheimer’s disease (AD), intracerebral hemorrhage (ICH), ischemic stroke (IS), traumatic brain injury (TBI), and others. In this review, we list these 74 FDA-approved kinase-targeted drugs and identify those that have been reported in preclinical and/or clinical trials for neurological disorders, with a purpose of discussing the feasibility and applicability of leveraging these cancer drugs (FDA-approved kinase inhibitors) for neurological treatments." @default.
- W4311397364 created "2022-12-26" @default.
- W4311397364 creator A5013685119 @default.
- W4311397364 creator A5014035858 @default.
- W4311397364 creator A5019962245 @default.
- W4311397364 creator A5024400728 @default.
- W4311397364 creator A5034502654 @default.
- W4311397364 creator A5065715792 @default.
- W4311397364 creator A5070704426 @default.
- W4311397364 creator A5074826426 @default.
- W4311397364 creator A5081850677 @default.
- W4311397364 creator A5083956786 @default.
- W4311397364 creator A5087634932 @default.
- W4311397364 date "2022-12-13" @default.
- W4311397364 modified "2023-10-17" @default.
- W4311397364 title "FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders" @default.
- W4311397364 cites W1036529846 @default.
- W4311397364 cites W117811691 @default.
- W4311397364 cites W1509604932 @default.
- W4311397364 cites W1545901128 @default.
- W4311397364 cites W1550675315 @default.
- W4311397364 cites W1556269168 @default.
- W4311397364 cites W1580068594 @default.
- W4311397364 cites W1594798896 @default.
- W4311397364 cites W1605375472 @default.
- W4311397364 cites W1618035875 @default.
- W4311397364 cites W1690266451 @default.
- W4311397364 cites W1691796058 @default.
- W4311397364 cites W1702956114 @default.
- W4311397364 cites W1760715174 @default.
- W4311397364 cites W1783847684 @default.
- W4311397364 cites W1834034354 @default.
- W4311397364 cites W1883048423 @default.
- W4311397364 cites W1883587302 @default.
- W4311397364 cites W1888003329 @default.
- W4311397364 cites W1904622810 @default.
- W4311397364 cites W1913458208 @default.
- W4311397364 cites W1920357305 @default.
- W4311397364 cites W1934889154 @default.
- W4311397364 cites W1938918694 @default.
- W4311397364 cites W1942602833 @default.
- W4311397364 cites W1948816881 @default.
- W4311397364 cites W1950705225 @default.
- W4311397364 cites W1957113161 @default.
- W4311397364 cites W1965180960 @default.
- W4311397364 cites W1968425934 @default.
- W4311397364 cites W1968962277 @default.
- W4311397364 cites W1970367429 @default.
- W4311397364 cites W1970480941 @default.
- W4311397364 cites W1970996370 @default.
- W4311397364 cites W1973415774 @default.
- W4311397364 cites W1974513180 @default.
- W4311397364 cites W1974775313 @default.
- W4311397364 cites W1976406567 @default.
- W4311397364 cites W1980142183 @default.
- W4311397364 cites W1984726207 @default.
- W4311397364 cites W1984987454 @default.
- W4311397364 cites W1985724300 @default.
- W4311397364 cites W1987679230 @default.
- W4311397364 cites W1989164587 @default.
- W4311397364 cites W1989723790 @default.
- W4311397364 cites W1989779456 @default.
- W4311397364 cites W1989929769 @default.
- W4311397364 cites W1990119512 @default.
- W4311397364 cites W1991016583 @default.
- W4311397364 cites W1991950284 @default.
- W4311397364 cites W1992266464 @default.
- W4311397364 cites W1992560177 @default.
- W4311397364 cites W1992597927 @default.
- W4311397364 cites W1993347204 @default.
- W4311397364 cites W1993746628 @default.
- W4311397364 cites W1994527362 @default.
- W4311397364 cites W1995363050 @default.
- W4311397364 cites W1996577359 @default.
- W4311397364 cites W1996648035 @default.
- W4311397364 cites W1996815931 @default.
- W4311397364 cites W1996921438 @default.
- W4311397364 cites W1997598438 @default.
- W4311397364 cites W1997801295 @default.
- W4311397364 cites W2000158949 @default.
- W4311397364 cites W2000797127 @default.
- W4311397364 cites W2000956676 @default.
- W4311397364 cites W2001389284 @default.
- W4311397364 cites W2002511732 @default.
- W4311397364 cites W2003643542 @default.
- W4311397364 cites W2004219186 @default.
- W4311397364 cites W2004892526 @default.
- W4311397364 cites W2007840958 @default.
- W4311397364 cites W2010671476 @default.
- W4311397364 cites W2011134915 @default.
- W4311397364 cites W2011896276 @default.
- W4311397364 cites W2012258115 @default.
- W4311397364 cites W2013874445 @default.
- W4311397364 cites W2014962014 @default.
- W4311397364 cites W2015128805 @default.
- W4311397364 cites W2017541725 @default.
- W4311397364 cites W2018105735 @default.
- W4311397364 cites W2024268760 @default.